ObjectivesDelta-like 1 homolog (DLK1) is a non-canonical Notch ligand known to be expressed in several cancers but whose role lung cancer not yet fully understood. We sought confirm DLK1 expression small-cell (SCLC) and non-small-cell (NSCLC), examine DLK1’s clinical significance. Furthermore, we examined the possible utility of as novel target radioimmunotherapy (RIT).MethodsWe retrospectively...

Bronchogenic carcinoma of the lung—lung cancer—comprises a group of malignant neoplasms that arise from bronchial epithelium. The four major pathologic cell types of lung cancer are small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because they have overlapping clinical behavior and response to treatment, adenocarcinoma, squamous cell carcinoma, and large ...

Non-small cell lung carcinoma (NSCLC) is the most common cancer globally. Phytochemicals and small molecule inhibitors significantly prevent varying types of cancers, including NSCLC. These therapeutic molecules serve as important sources for new drugs that interfere with cellular proliferation, apoptosis, metastasis, angiogenesis by regulating signaling pathways. affect several cascades, p53, ...

To determine the role of miR-25 in non-small cell lung cancer (NSCLC), we first detected miR-25 expression in clinical specimens and lung cancer cell lines by quantitative real-time polymerase chain reaction. The levels of miR-25 were elevated in the plasma of NSCLC patients and NSCLC cell lines. Transfection of A549 and 95-D cells with a miR-25 inhibitor resulted in reduced cell proliferation ...

Non-small cell lung cancer (NSCLC), accounts for approximately 80-85% of all lung cancer cases, is the most common cause of cancer-related death worldwide. With the advances of high-throughput sequencing, accumulating evidence suggested that the long non-coding RNA molecules, with transcripts larger than 200 nucleotides, have important roles in multiple biological processes in NSCLC. In this re...

• Across Europe, the clinical and economic burden of advanced non-small cell lung cancer (aNSCLC) is high. • Approximately 20% of cancer mortality in European men and women is due to lung cancer; the most common lung cancer type is non-small cell lung cancer (NSCLC) which accounts for approximately 85% of all lung cancer diagnoses [1]. • Little is known about the real-world treatment, as well a...

Lung cancer continues to be the leading cause of cancer death worldwide, and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Molecular targeted therapy is the most promising development part in the treatment of NSCLC. In recent years, more and more attention has been focused on some new molecular targets in NSCLC, such as echinodem microtubule-associated protein-like4...

Lung cancer is the most common human cancer, and the majority of lung cancer cases are categorized as non-small cell lung cancer (NSCLC). Long non-coding RNAs (lncRNAs) play key roles in the development and progression of human cancers. LncRNA breast cancer anti-estrogen resistance 4 (BCAR4) has been identified as an oncogenic lncRNA involved in the progression of breast cancer and osteosarcoma...

Background: Boron neutron capture therapy (BNCT) is a radiotherapy that combines biological targeting and high linear energy transfer. A potential therapeutic approach for non-small cell lung cancer (NSCLC) is considered. However, dose in lung tumor is not homogeneous, and it will reduce the effect of BNCT treatment. In order to improve the dose distribution of BNCT, the multi-field irradiation...

INTRODUCTION Non-small cell lung cancer (NSCLC) is the major cause of cancer death worldwide. Increasing evidence shows that long non coding RNAs (lncRNAs) are widely involved in the development and progression of NSCLC. lncRNA PVT1 in several cancers has been studied, its role in lung cancer remains unknown. Our studies were designed to investigate the expression, biological role and clinical ...